SoLo Eye Care is a proud provider of Macula Risk PGx

Age-related Macular Degeneration is predominantly an inherited disease. Macula Risk is a prognostic DNA test that identifies individuals who have inherited any of the disease-causing genes. These individuals are at increased risk of vision loss as they age.

Macula Risk PGx is an in-office test designed to determine a patient's risk of progression to advanced Age-related Macular Degeneration (AMD) and aid in the selection of appropriate eye vitamin therapies based on his or her individual genetic risk profile. Macula Risk PGx predicts a patient's risk of progression to advanced AMD with vision loss within 2, 5 and 10 years. Validated risk determinations of two large and independent populations show test sensitivity and specificity each greater than 80% and a 10-year predictive accuracy of 89.5%1.

The in-office test requires a painless, simple swab of the inner cheek; no blood is drawn.

Macula Risk identifies individuals (1 in every 5 patients) that are at highest risk of vision loss due to AMD. Identifying these patients early allows the eye-care professional to implement a disease management strategy focused on sight preservation.

Increased risk (Macula Risk® Level 3, 4 and 5) patients may benefit from:

Increased frequency of eye examinations
Disease education and possibly ‘at-home’ Amsler Grid or Home PHP testing
Preventative eye vitamin therapy and possibly nutritional supplements
Early diagnosis and treatment of wet AMD with effective therapies

Results are usually obtained within three to four weeks. Once the results are received, SoLo Eye Care will contact you for an appointment so that a preventative treatment plan can be developed.

Call today to determine if you or a loved one are at risk.